KR102666879B1 - 항-tslp 항체를 이용한 천식의 치료 - Google Patents

항-tslp 항체를 이용한 천식의 치료 Download PDF

Info

Publication number
KR102666879B1
KR102666879B1 KR1020197033043A KR20197033043A KR102666879B1 KR 102666879 B1 KR102666879 B1 KR 102666879B1 KR 1020197033043 A KR1020197033043 A KR 1020197033043A KR 20197033043 A KR20197033043 A KR 20197033043A KR 102666879 B1 KR102666879 B1 KR 102666879B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
set forth
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033043A
Other languages
English (en)
Korean (ko)
Other versions
KR20190140956A (ko
Inventor
제인 알. 파르네스
자넷 그리피스
Original Assignee
암젠 인크
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크, 메디뮨 엘엘씨 filed Critical 암젠 인크
Priority to KR1020247015858A priority Critical patent/KR20240070727A/ko
Publication of KR20190140956A publication Critical patent/KR20190140956A/ko
Application granted granted Critical
Publication of KR102666879B1 publication Critical patent/KR102666879B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197033043A 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료 Active KR102666879B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247015858A KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US62/484,864 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01
US62/553,477 2017-09-01
US62/553,575 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015858A Division KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Publications (2)

Publication Number Publication Date
KR20190140956A KR20190140956A (ko) 2019-12-20
KR102666879B1 true KR102666879B1 (ko) 2024-05-23

Family

ID=62092313

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247015858A Pending KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료
KR1020197033043A Active KR102666879B1 (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020247015858A Pending KR20240070727A (ko) 2017-04-12 2018-04-12 항-tslp 항체를 이용한 천식의 치료

Country Status (21)

Country Link
US (3) US10828365B2 (enExample)
EP (1) EP3609917A1 (enExample)
JP (4) JP7330896B2 (enExample)
KR (2) KR20240070727A (enExample)
CN (1) CN110573525A (enExample)
AU (2) AU2018253118B2 (enExample)
BR (1) BR112019021482A2 (enExample)
CA (1) CA3059364A1 (enExample)
CL (1) CL2019002897A1 (enExample)
CO (1) CO2019011462A2 (enExample)
IL (1) IL269791B (enExample)
JO (1) JOP20190243A1 (enExample)
MX (1) MX2019012158A (enExample)
MY (1) MY207509A (enExample)
PE (1) PE20200484A1 (enExample)
PH (1) PH12019502331A1 (enExample)
SG (1) SG11201909322VA (enExample)
TN (1) TN2019000289A1 (enExample)
TW (2) TWI856945B (enExample)
UY (1) UY37676A (enExample)
WO (1) WO2018191479A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347377B1 (en) * 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
AU2020311432A1 (en) * 2019-07-11 2022-02-03 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合ｔｓｌｐ及びその使用
RS66646B1 (sr) * 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN115279404A (zh) * 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
WO2021163588A1 (en) * 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
MX2023009971A (es) * 2021-03-03 2023-09-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composicion farmaceutica que contiene anticuerpo anti-tslp.
KR20230172508A (ko) * 2021-04-19 2023-12-22 메디뮨 리미티드 안정성이 개선된 항-tslp fab
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
TW202523697A (zh) * 2023-08-25 2025-06-16 美商普羅特歐拉吉克適美國公司 抗ｔｓｌｐ抗體構築體及其用途
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
MX2017001531A (es) * 2014-08-08 2017-05-15 Alector Llc Anticuerpos anti-trem2 y metodos de uso de los mismos.
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEW ENGLAND JOURNAL OF MEDICINE(2014), vol.370, no.22, pp2102-2110(2014.05.24.) 1부.*

Also Published As

Publication number Publication date
KR20190140956A (ko) 2019-12-20
TW201838652A (zh) 2018-11-01
JP2024150751A (ja) 2024-10-23
AU2018253118A1 (en) 2019-10-24
IL269791B (en) 2022-07-01
SG11201909322VA (en) 2019-11-28
CL2019002897A1 (es) 2020-03-06
TWI856945B (zh) 2024-10-01
CN110573525A (zh) 2019-12-13
KR20240070727A (ko) 2024-05-21
US10828365B2 (en) 2020-11-10
US20250032608A1 (en) 2025-01-30
US20210052726A1 (en) 2021-02-25
MX2019012158A (es) 2019-12-16
EP3609917A1 (en) 2020-02-19
CA3059364A1 (en) 2018-10-18
TW202523688A (zh) 2025-06-16
BR112019021482A2 (pt) 2020-05-12
AU2025204735A1 (en) 2025-07-17
PH12019502331A1 (en) 2020-09-28
CO2019011462A2 (es) 2019-10-31
AU2018253118B2 (en) 2025-04-10
TN2019000289A1 (en) 2021-05-07
JOP20190243A1 (ar) 2019-10-13
JP2023099233A (ja) 2023-07-11
IL269791A (en) 2019-11-28
PE20200484A1 (es) 2020-03-03
JP7330896B2 (ja) 2023-08-22
UY37676A (es) 2018-10-31
JP2025170430A (ja) 2025-11-18
US20180296669A1 (en) 2018-10-18
WO2018191479A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
JP2020516647A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
KR102666879B1 (ko) 항-tslp 항체를 이용한 천식의 치료
KR20230175245A (ko) 변형된 항-tslp 항체
KR20220143699A (ko) 인간 항-tslp 항체 제형 및 이의 이용 방법
US20230073888A1 (en) Treatment of atopic dermatitis with anti-tslp antibody
IL302445A (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
KR20250140101A (ko) 항-tslp 항체를 이용한 만성 비부비동염의 치료
AU2024274293A1 (en) Treatment of corticosteroid dependent asthma with anti-tslp antibody
AU2024274293A9 (en) Treatment of corticosteroid dependent asthma with anti-tslp antibody
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025120567A1 (en) Method of treatment of asthma
WO2025147632A1 (en) Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
US20140248289A1 (en) Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210412

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230227

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230821

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230821

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230427

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210412

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240207

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240122

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230821

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230427

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210412

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240513

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240513

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240514

End annual number: 3

Start annual number: 1

PG1601 Publication of registration